亚洲人成电影网站色www- 亚洲人成视频免费视频- 亚洲人成网站视频

    1. <form id=EOsVBoWLp><nobr id=EOsVBoWLp></nobr></form>
      <address id=EOsVBoWLp><nobr id=EOsVBoWLp><nobr id=EOsVBoWLp></nobr></nobr></address>

      您好,歡迎訪問中山大學腫瘤防治中心官方網站!
      內部網 職工郵箱 圖書館 OA系統 醫生門戶 English
      院士風采 首席專家 临床專家 科研學者 客座教授 人才名錄 护理專家
      首頁
      • 夏建川

        職務:生物治療中心主任
        職稱:教授、醫學博士、博士生導師
        專長:特別擅長腫瘤的免疫細胞治療。
        主要簡介 詳細介紹 預約挂號
          夏建川,教授、医学博士、博士生导师,哈佛大学Dana-Farber肿瘤研究所博士后,享受国务院政府特殊津贴,现任中山大學附属肿瘤医院生物治疗中心主任,体细胞治疗与保健研究中心主任,亚太医学生物免疫学会主任委员,中国细胞治疗质量控制和研究专业委员会主任委员,中国生物治疗临床应用专业委员会副主任委员,中国医药生物技术协会常务理事,中国细胞学会常务理事,广东省细胞生物学学会理事长,廣東省抗癌協會生物治疗专业委员会主任委员,国家食品和药品监督管理局新药评审專家,国家华南肿瘤学重点实验室免疫与遗传研究课题组组长。美国《Cancer Letter》杂志编委,《癌症》杂志常务编委,国家自然基金和广东省自然基金重点项目评审專家。

          夏建川教授 1998年毕业于哈尔滨医科大学,获医学博士学位;1998-2000年在中山大學附属肿瘤医院从事肿瘤学博士后研究工作;2000-2003年在哈佛大学Dana-Farber肿瘤研究所从事肿瘤的免疫治疗和肿瘤疫苗的研究。在此期间,首次证实DC/肿瘤融合细胞疫苗能诱导自发性乳腺癌转基因小鼠产生抗肿瘤免疫应答,为DC/肿瘤融合细胞疫苗在临床治疗肿瘤中的应用奠定了基础,研究成果发表在美国免疫学专业杂志(The Journal of Immunology 2003 and 2004)。2003年12月回国,利用在国外学到的先进分子生物学和肿瘤免疫学技术,积极开展肿瘤病因学和免疫治疗的基础与临床应用研究。在鼻咽癌、肺癌、乳腺癌、胃癌、肠癌、肝癌和肾癌等恶性肿瘤的发病机制,以及肿瘤微环境、肿瘤干细胞、免疫细胞相互作用和免疫细胞治疗的临床应用等方面做出了突破性工作。在国内率先建立了肿瘤体细胞制备技术操作规范、肿瘤体细胞临床应用安全检测标准和体细胞免疫治疗临床应用规范,为我国制定了第一个“自体免疫细胞(T细胞、NK细胞)治疗技术管理规范”,使体细胞免疫治疗向规范道路上迈出了重要的一步,为我国细胞免疫治疗在规范化的基础上开展临床应用做出了重要贡献。主编了国内第一部《肿瘤生物治疗基础与临床应用》 的教材(科学出版社出版),作为国家重点研发项目的首席科学家主持包括国家重点研发项目、国家重大卫生公益事业课题、國家自然科學基金和省部级重大研究项目24项,以第一或通迅作者在高水平收录的科学杂志发表研究论文84篇;包括在Nat Genetics;Clinic Cancer Res;Journal for Immuno Therapy of Cancrer;Journal of Hematology & Oncology;Clinical &  translational immunology;The Journal of Immunology和Stem Cells等高水平科学杂志上发表研究论文。作为第一发明人申请發明專利4项,其中授权3项。荣获首届广州新侨留学生回国创业贡献奖。 

          專家门诊时间:每周一的上午,肿瘤的免疫治疗。
          專業特長:長期從事腫瘤的病因學和腫瘤免疫細胞治療的基礎和臨床應用研究。特別擅長腫瘤的免疫細胞治療。

          夏建川,教授 医学博士、博士生导师,哈佛大学Dana-Farber肿瘤研究所博士后,享受国务院政府特殊津贴,现任中山大學附属肿瘤医院生物治疗中心主任,体细胞治疗与保健研究中心主任,亚太医学生物免疫学会主任委员,中国细胞治疗质量控制和研究专业委员会主任委员,中国研究型医院学会生物治疗学专业委员会副主任委员,中国生物治疗临床应用专业委员会副主任委员,中国医药生物技术协会常务理事,中国细胞学会常务理事,广东省细胞生物学学会理事长,廣東省抗癌協會生物治疗专业委员会主任委员,国家食品和药品监督管理局新药评审專家,国家华南肿瘤学重点实验室免疫与遗传研究课题组组长。美国《Cancer Letter》杂志编委,《癌症》杂志常务编委,国家自然基金和广东省自然基金重点项目评审專家。

          夏建川 教授 1998年毕业于哈尔滨医科大学,获医学博士学位; 1998-2000年在中山医科大学附属肿瘤医院从事博士后研究工作;2000-2003年在哈佛大学Dana-Farber肿瘤研究所从事肿瘤的免疫治疗和肿瘤疫苗的研究。在此期间,首次证实DC/肿瘤融合细胞疫苗能诱导自发性乳腺癌转基因小鼠产生抗肿瘤免疫应答,为DC/肿瘤融合细胞疫苗在临床治疗肿瘤中的应用奠定了基础,研究成果发表在美国免疫学专业杂志上(J Immunol 2003 Feb 15;170 (4):1980-1986;J Immunol, 2004, 172: 7848-7858;Immunology. 2003 Jun;109(2):300-7),2003年12月回国,利用在国外学到的先进体细胞免疫治疗技术,积极开展肿瘤体细胞免疫治疗的基础和临床应用研究,在国内率先建立了体细胞制备技术操作规范、体细胞临床应用安全检测标准和体细胞免疫治疗临床应用规范,使体细胞免疫治疗向规范道路上迈出了重要的一步,为肿瘤的体细胞免疫治疗在临床治疗过程中安全、有效的应用做出了重要贡献。

          近年來,主持並參與多項國家和省部級重大臨床應用研究項目,積極開展腫瘤病因學和腫瘤體細胞免疫治療的基礎和臨床應用研究,在腫瘤病因學和腫瘤體細胞免疫治療領域發表高水平收入的研究論文80余篇。主編了國內第一部《腫瘤生物治療基礎與臨床應用 的教材(中國科技出版社2011年8月出版);作爲副主編編寫了《個體化醫學原則》專著(由人民衛生出版社2013年1月出版);參編了醫學高等院校本科教材臨床腫瘤學》和医学高等院校研究生教材《臨床腫瘤學》等專著。获得三项国家發明專利(一种人肿瘤细胞分离纯化的技术 国家發明專利号:ZL 03146933.7);(用于刺激树突状细胞成熟的组合物以及方法 国家發明專利号:ZL 2013 1 0049402.6);DC-CIK细胞和抗PD-1抗体组合物及其用途 国家發明專利号ZL 2017 1 0090026.3)。曾获得省政府科技进步二等奖,2008年首届广州新侨留学生回国创业贡献奖。


        主要研究方向

        一、醫學研究
        1、腫瘤的體細胞免疫治療研究
          主要致力于體細胞免疫治療的臨床應用研究,包括腫瘤樹突狀細胞疫苗(DC疫苗),DC/腫瘤融合細胞疫苗、腺相關病毒介導腫瘤抗原轉導的DC疫苗(DC-T細胞),細胞因子誘導的殺傷細胞(CIK細胞),DC刺激的CIK細胞(DC-CIK),自然殺傷細胞(NK細胞)和腫瘤浸潤性淋巴細胞等。在腫瘤體細胞免疫治療的臨床應用過程中,爲了保證臨床安全和療效,制定了體細胞制備流程和臨床應用規範化准則,同時經過對大量接受體細胞免疫治療患者療效的觀察和臨床試驗研究,建立了多種臨床腫瘤體細胞免疫治療的方案,在腫瘤體細胞免疫治療的臨床應用過程中,爲提高體細胞免疫治療在腫瘤臨床中的療效,經過大量的臨床試驗研究,在國內提出了腫瘤常規治療聯合體細胞免疫治療的增效方案,爲腫瘤患者在常規治療(手術、化療和放療)後的鞏固治療提供了一種新的治療手段。並在前期臨床試用研究的基礎上,率先提出要根據病人的腫瘤特征、遺傳背景、病情狀況、年齡等制定出適合病人的個體化體細胞免疫治療策略,並建立了多種臨床腫瘤體細胞免疫治療的具體方案,爲體細胞免疫治療在臨床腫瘤治療中安全、有效的應用起到了關鍵性作用,真正實現了基礎研究的成果向臨床應用的快速轉化。這些體細胞免疫治療的具體方案包括:1、對年齡偏大的老年腫瘤患者采取少量抽血多次回輸的方案,對抑制腫瘤的複發和轉移取得了較好效果;2、率先提出在化療或放療間隙過程中聯合體細胞免疫治療的增效治療方案,該治療方案打破了長期以來認爲化療或放療與體細胞免疫治療不能聯合使用的傳統觀點,爲保護腫瘤患者免疫功能,提高療效起到了積極的作用;3、率先提出了在腫瘤治療過程中把不同的抗腫瘤免疫活性細胞交替使用的治療方案,以防止一種抗腫瘤免疫效應細胞長期使用可能帶來的免疫耐受,在臨床上起到了較好的效果;4、率先提出把體細胞免疫治療聯合抗腫瘤的細胞因子、抗腫瘤抗體、生物分子靶向藥物聯合應用的增效治療方案;5、率先提出在原發性肝癌手術或微創介入治療後進行體細胞免疫治療以抑制腫瘤複發和轉移的個體化治療模式,對有效抑制肝癌的複發和轉移,提高原發性肝癌的療效起到了較好的作用。目前,這些體細胞免疫治療方案已在臨床腫瘤治療過程中得到廣泛應用,爲體細胞免疫治療在臨床腫瘤治療過程中的規範化應用起到了重要作用,真正實現了基礎研究的成果向臨床應用的轉化。

          基于上述開拓性的工作,極大的推動了腫瘤體細胞免疫治療在臨床腫瘤中的應用,目前中山大學附屬腫瘤醫院生物治療中心已成爲“華南生物治療基地”挂靠單位,這個基地將爲生物治療的臨床應用、新項目的研發、人才培養和國際合作提供良好的平台,爲推動我國腫瘤體細胞免疫治療在規範化應用的基礎上健康有序的發展將發揮重要作用。

        2、腫瘤病因學的研究
          主要致力于胃癌,肝癌和腎癌發病機制的研究,包括篩選與上述腫瘤密切相關的抑癌基因和癌基因,並進行相關功能的研究,同時結合臨床,研究這些基因與臨床療效和預後之間的關系,爲將來發展腫瘤新的有效治療方法奠定實驗基礎。

        3、近年来获得的科研基金項目

        課題名稱

        課題類別

        項目編號

        研究年限

        資助金額

        靶向惡性實體腫瘤免疫細胞治療新技術的研發及其臨床轉化路徑的規範化建立

         

         

        國家級國家重點研發計劃項目

         

         

        2018YFC1313400

         

         

        2018—2020

         

         

        1513萬

         

         

        精准靶向腫瘤相關抗原和T細胞免疫抑制相關受體及細胞免疫治療新技術的建立

         

         

        省部級廣東省省計劃項目重點項目

         

         

        2017B020227003

         

         

        2017-2019

         

         

        300萬

         

         

        Galectin-3通過β-Catenin信號通路調控血管生成促進肝癌轉移分子機制的初步研究

         

         

        國家級國家自然科學基金面上項目

         

         

        81773110

         

         

        2017-2021

         

         

        55萬

         

         

        靶向腫瘤特異性抗原的精准免疫細胞治療新技術研發和臨床應用(附一牽頭)

         

         

        廣州市健康醫療協同創新重大專項

         

         

        201704020215

         

         

        2017-2020

         

         

        175萬

         

         

        TESTIN基因抑制胃癌細胞轉移分子機制的初步研究

         

         

        國家級國家自然科學基金面上項目

         

         

        81572865

         

         

        2016-2019

         

         

        68.4萬

         

         

        TESTIN基因抑制胃癌細胞轉移分子機制的初步研究

         

         

        省部級廣東省省自然科學基金重點項目

         

         

        S2013020012722

         

         

        2013-2016

         

         

        20 万

         

         

        IL-17細胞因子及Th17抗原特異性淋巴細胞抗食管癌作用及機制研究

         

         

        國家自然科學基金

         

         

        31270964

         

         

        2012-2016

         

         

        80萬

         

         

        靶向腎癌幹細胞的特異性免疫治療研究

         

         

        廣東省科技計劃項目

         

         

        2012A030400059

         

         

        2013-2015

         

         

        20萬

         

         

        靶向腎癌幹細胞的特異性免疫治療研究

         

         

        省部級廣州市廣州市計劃項目

         

         

        2013J4500005

         

         

        2013-

         

         

        2015

         

         

        30 万元

         

         

        肝癌干细胞特异性抗原筛选及诱导特异性CTL 研究

         

         

        廣東省科技計劃項目

         

         

        2011A030400004

         

         

        2012-2014

         

         

        50萬

         

         

        胃癌中TESTIN基因失活機制及功能的初步研究

         

         

        國家自然科學基金

         

         

        30973398

         

         

        2010-2012

         

         

        32萬

         

         

        胃癌中TESTIN基因失活機制及功能的初步研究

         

         

        廣東省自然科學基金重點項目

         

         

        925100890

         

         

        2010-2012

         

         

        20萬

         

         

        免疫治療與體細胞治療相關技術標准研究

         

         

        衛生部

         

         

        200902002-2

         

         

        2009-2012

         

         

        265萬

         

         

        肝癌幹細胞/DC疫苗增強抗肝癌免疫應答及機制研究

         

         

        國家自然科學基金

         

         

        u0772002

         

         

        2008-2010

         

         

        30萬

         

         

        RAK聯合射頻消融術治療小肝癌的臨床研究

         

         

        與日本TAKARA公司合作研究

         

         

         

         

        2008-2010

         

         

         

        200萬

         

         

        抑制SOCS1基因表達聯合OK-PSA刺激對樹突狀細胞抗肝癌免疫應答的影響及機制

         

         

        國家自然科學基金

         

         

        30571717

         

         

        2006-2008

         

         

        28萬

         

         

        胃癌D7S486位點附近抑癌基因的鑒定

         

         

        高等學校博士點專項科研基金

         

         

        20050558055

         

         

        2006-2008

         

         

        6萬

         

         

        胃癌D7S486位點附近抑癌基因的鑒定

         

         

        國家自然科學基金

         

         

        30471950

         

         

        2005-2007

         

         

        21萬

         

         

        胃癌D7S486位點附近抑癌基因的鑒定

         

         

        廣東省自然科學基金重點項目

         

         

        04105350

         

         

        2005-2007

         

         

        15萬

         

         

        胃癌D7S位點附近抑癌基因的鑒定

         

         

        廣州市科技攻關引導項目

         

         

        2005-23-I0491

         

         

        2005-2007

         

         

        20萬

         

         

        自體DC與腎癌細胞融合疫苗治療晚期腎癌患者的臨床試驗研究

         

         

        廣東省科技計劃項目

         

         

        2004B30301017

         

         

        2005-2007

         

         

        15萬

         

         

        自體DC/腎癌融合細胞疫苗治療晚期腎癌的臨床應用研究

         

         

        廣東省衛生廳重點項目

         

         

        WSTJJ20030305

         

         

        2005-2007

         

         

         

        15萬

         

         

        自體DC/食道癌融合細胞疫苗治療晚期食道癌的臨床應用研究

         

         

         

        廣州市科技攻關引導項目

         

         

         

        2004Z3-E0311

         

         

         

        2004-2006

         

         

         

        15萬

         

         

        胃癌7q32-qter區域的缺失及克隆研究

         

         

        國家自然科學基金

         

         

        30070840

         

         

        2001-2003

         

         

        16萬

         

         


        4、社會兼職

          亚太医学生物免疫学会主任委员,中国细胞治疗质量控制和研究专业委员会主任委员,中国研究型医院学会生物治疗学专业委员会副主任委员,中国生物治疗临床应用专业委员会副主任委员,中国医药生物技术协会常务理事,中国细胞学会常务理事,广东省细胞生物学学会理事长,廣東省抗癌協會生物治疗专业委员会主任委员,国家食品和药品监督管理局新药评审專家,国家华南肿瘤学重点实验室免疫与遗传研究课题组组长。美国《Cancer Letter》杂志编委,《癌症》杂志常务编委,国家自然基金和广东省自然基金重点项目评审專家。

        5、個人榮譽及作品

        獲獎情況
        (1)省科學技術進步二等獎;

        (2)省教委科技進步獎一等獎;

        (3)2008年首屆廣州新僑留學生回國創業貢獻獎

        專著

        主編《腫瘤生物治療基礎與臨床應用》,北京,科學出版社,2011年

        副主编《个体化医学原则》專著(由人民卫生出版社2013年1月出版);

        獲得專利
        国家發明專利(专利号:ZL 03146933.7) “一种分离纯化人肿瘤细胞的方法”

        国家發明專利(专利号:ZL 2013 1 0049402.6) “用于刺激树突状细胞成熟的组合物以及方法 ”

        国家發明專利(专利号ZL 2017 1 0090026.3)  “DC-CIK细胞和抗PD-1抗体组合物及其用途”


        發表論文

        1.     Pan QZ, Gu JM, Zhao JJ, Tang Y, Wang QJ, Zhu Q, Song MJ, Li YQ, He J, Chen SP, Weng DS, Xia JC(Corresponding). Retrospective analysis of the efficacy of cytokine-induced killer cell immunotherapy combined with first-line chemotherapy in patients with metastatic colorectal cancer. Clin Transl Immunology. 2020 Feb 19;9(2)

        2.     Pan QZ, Liu Q, Zhou YQ, Zhao JJ, Wang QJ, Li YQ, Tang Y, Gu JM, He J, Chen SP, Weng DS, Xia JC(Corresponding). CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2020 Feb 14.

        3.     Huang XQ, Hao S, Zhou ZQ, Huang B, Fang JY, Tang Y, Zhang JH, Xia JC(Corresponding).The Roles of Ubiquitination Factor E4B (UBE4B) in the Postoperative Prognosis of Patients with Renal Cell Carcinoma and in Renal Tumor Cells Growth and Metastasis. Onco Targets Ther. 2020 Jan 8;13:185-197

        4.     Zhu Q, Zhong AL, Hu H, Zhao JJ, Weng DS, Tang Y, Pan QZ, Zhou ZQ, Song MJ, Yang JY, He JY, Liu Y, Li M, Hu WM, Yang CP, Xiang T, Chen MY, Ma G, Guo L, Xia JC(Corresponding). Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma.J Hematol Oncol. 2020 Jan 3;13(1):2.

        5.     Song M, Zhong A, Yang J, He J, Cheng S, Zeng J, Huang Y, Pan Q, Zhao J, Zhou Z, Zhu Q, Tang Y, Chen H, Yang C, Liu Y, Mo X, Weng D, Xia JC(Corresponding).Large-scale analyses identify a cluster of novel long noncoding RNAs as potential competitive endogenous RNAs in progression of hepatocellular carcinoma. Aging (Albany NY). 2019 Nov 23;11(22):10422-10453.

        6.     Zhou ZQ, Zhao JJ, Pan QZ, Chen CL, Liu Y, Tang Y, Zhu Q, Weng DS, Xia JC(Corresponding). PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer. J Immunother Cancer. 2019 Aug 27;7(1):228.

        7.     Liu Y, Zhao JJ, Zhou ZQ, Pan QZ, Zhu Q, Tang Y, Xia JC(Corresponding), Weng DS. IL-37 induces anti-tumor immunity by indirectly promoting dendritic cell recruitment and activation in hepatocellular carcinoma. Cancer Manag Res. 2019 Jul 18;11:6691-6702.

        8.     Zhu Q, Cai MY, Weng DS, Zhao JJ, Pan QZ, Wang QJ, Tang Y, He J, Li M, Xia JC(Corresponding). PD-L1 expression patterns in tumour cells and their association with CD8+ tumour infiltrating lymphocytes in clear cell renal cell carcinoma. J Cancer. 2019 Jan 29;10(5):1154-1161.

        9.     Wang DD, Chen YB, Zhao JJ, Zhang XF, Zhu GC, Weng DS, Pan K, Lv L, Pan QZ, Jiang SS, Wang LL, Xia JC(Corresponding). TES functions as a Mena-dependent tumor suppressor in gastric cancer carcinogenesis and metastasis. Cancer Commun (Lond). 2019 Feb 6;39(1):3.

        10.   Zhou Y, Chen CL, Jiang SW, Feng Y, Yuan L, Chen P, Zhang L, Huang S, Li J, Xia JC(Corresponding), Zheng M. Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy. Oncoimmunology. 2018 Nov 11;8(2):

        11.   Zhao JJ, Zhou ZQ, Wang P, Chen CL, Liu Y, Pan QZ, Zhu Q, Tang Y, Weng DS, Xia JC(Corresponding). Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma. Cancer Manag Res. 2018 Nov 28;10:6457-6468.

        12.   Zhao JJ, Zhou S, Chen CL, Zhang HX, Zhou ZQ, Wu ZR, Liu Y, Pan QZ, Zhu Q, Tang Y, Xia JC(Corresponding), Weng DS. Clinical Effect of Adjuvant Cytokine-Induced Killer Cells Immunotherapy in Patients with Stage II-IVB Nasopharyngeal Carcinoma after Chemoradiotherapy: A propensity score analysis. J Cancer. 2018 Oct 20;9(22):4204-4214.

        13.   Zhu Q, Hu H, Tang LQ, You R, Zhao JJ, Weng DS, Pan QZ, Chen CL, Zhou ZQ, Tang Y, Xia JC(Corresponding). Weekly versus triweekly cisplatin plus intensity-modulated radiotherapy in locally advanced nasopharyngeal carcinoma: A propensity score analysis with a large cohort. J Cancer. 2018 Sep 8;9(19):3447-3455. .

        14.   Zhou ZQ, Zhao JJ, Chen CL, Liu Y, Zeng JX, Wu ZR, Tang Y, Zhu Q, Weng DS, Xia JC(Corresponding). HUS1 checkpoint clamp component (HUS1) is a potential tumor suppressor in primary hepatocellular carcinoma. Mol Carcinog. 2018 Sep 4.

        15.   Chen CL, Pan QZ, Weng DS, Xie CM, Zhao JJ, Chen MS, Peng RQ, Li DD, Wang Y, Tang Y, Wang QJ, Zhang ZL, Zhang XF, Jiang LJ, Zhou ZQ, Zhu Q, He J, Liu Y, Zhou FJ, Xia JC(Corresponding).Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors.Oncoimmunology. 2018 Jan 10;7(4)

        16.   Chen CL, Wang Y, Huang CY, Zhou ZQ, Zhao JJ, Zhang XF, Pan QZ, Wu JX, Weng DS, Tang Y, Zhu Q, Yuan LP, Xia JC(Corresponding).IL-17 induces antitumor immunity by promoting beneficial neutrophil recruitment and activation in esophageal squamous cell carcinoma.Oncoimmunology. 2017 Sep 21;7(1)

        17.   Huang XQ, Zhou ZQ, Zhang XF, Chen CL, Tang Y, Zhu Q, Zhang JH, Xia JC(Corresponding).Overexpression of SMOC2 Attenuates the Tumorigenicity of Hepatocellular Carcinoma Cells and Is Associated With a Positive Postoperative Prognosis in Human Hepatocellular Carcinoma. J Cancer. 2017 Oct 17;8(18):3812-3827.

        18.   Huang XQ, Zhang XF, Xia JH, Chao J, Pan QZ, Zhao JJ, Zhou ZQ, Chen CL, Tang Y, Weng DS, Zhang JH, Xia JC(Corresponding). Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer.Chin J Cancer. 2017 Sep 26;36(1):77

        19.   Zhu Q, Cai MY, Chen CL, Hu H, Lin HX, Li M, Weng DS, Zhao JJ, Guo L, Xia JC(Corresponding).Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. Oncoimmunology. 2017 Apr 27;6(5)

        20.   Zhang XF, Weng DS, Pan K, Zhou ZQ, Pan QZ, Zhao JJ, Tang Y, Jiang SS, Chen CL, Li YQ, Zhang HX, Chang AE, Wicha MS, Zeng YX, Li Q, Xia JC(Corresponding).Dendritic-cell-based immunotherapy evokes potent anti-tumor immune responses in CD105+ human renal cancer stem cells.Mol Carcinog. 2017 Nov;56(11):2499-2511

        21.   Zhu Q, Hu H, Weng DS, Zhang XF, Chen CL, Zhou ZQ, Tang Y, Xia JC(Corresponding). Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC.BMC Cancer. 2017 Jun 12;17(1):412

        22.   Jiang SS, Jiang L, Weng DS, Li YF, Pan QZ, Zhao JJ, Tang Y, Zhou ZW, Xia JC(Corresponding). Immunization-based scores as independent prognostic predictors in soft tissue sarcoma patients. J Cancer. 2017 Feb 25;8(4):606-616.

        23.   Chen CL, Pan QZ, Zhao JJ, Wang Y, Li YQ, Wang QJ, Pan K, Weng DS, Jiang SS, Tang Y, Zhang XF, Zhang HX, Zhou ZQ, Zeng YX, Xia JC(Corresponding). PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Oncoimmunology. 2016 May 31;5(7)

        24.   Jiang SS, Weng DS, Jiang L, Zhang YJ, Pan K, Pan QZ, Chen CL, Zhao JJ, Zhang XF, Zhang HX, Tang Y, Zhou ZQ, Chen MS, Xia JC(Corresponding). The clinical significance of preoperative serum cholesterol and high-density lipoprotein-cholesterol levels in hepatocellular carcinoma. J Cancer. 2016 Mar 20;7(6):626-32.

        25.   Zhang XF, Pan K, Weng DS, Chen CL, Wang QJ, Zhao JJ, Pan QZ, Liu Q, Jiang SS, Li YQ, Zhang HX, Xia JC(Corresponding). Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis. Oncotarget. 2016 May 3;7(18):26670-9

        26.   Xu L, Wang J, Kim Y, Shuang ZY, Zhang YJ, Lao XM, Li YQ, Chen MS, Pawlik TM, Xia JC(Corresponding), Li SP, Lau WY. A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. Oncoimmunology. 2015 Oct 12; 5(3) :e1083671.

        27.   Pan QZ, Tang Y, Wang QJ, Li YQ, Zhang L, Li XD, Zhao JJ, Weng DS, Liu Q, Huang LX, He J, Chen SP, Ke ML, Zeng YX, Xia JC(Corresponding). Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer. Oncoimmunology. 2015 May 27;4(9)

        28.   Jiang SS, Tang Y, Zhang YJ, Weng DS, Zhou ZG, Pan K, Pan QZ, Wang QJ, Liu Q, He J, Zhao JJ, Li J, Chen MS, Chang AE, Li Q, Xia JC(Corresponding). A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. Oncotarget 2015;6:41339-49.

        29.   Zhang XF, Pan QZ, Pan K, Weng DS, Wang QJ, Zhao JJ, He J, Liu Q, Wang DD, Jiang SS, Zheng HX, Lv L, Chen CL, Zhang HX, Xia JC(Corresponding). Expression and prognostic role of ubiquitination factor E4B in primary hepatocellular carcinoma. Mol Carcinog. 2015 Jan 3.

        30.   Pan QZ, Pan K, Wang QJ, Weng DS, Zhao JJ, Zheng HX, Zhang XF, Jiang SS, Lv L, Tang Y, Li YQ, He J, Liu Q, Chen CL, Zhang HX, Xia JC(Corresponding). Annexin A3 as a Potential Target for Immunotherapy of Liver Cancer Stem‐Like Cells. Stem Cells. 2014 Sep 29.

        31.   Jiang SS, Weng DS, Wang QJ, Pan K, Zhang YJ, Li YQ, Li JJ, Zhao JJ, He J, Lv L, Pan QZ, Xia JC(Corresponding). Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma. J Transl Med. 2014 Sep 27;12(1):273.

        32.   Chao J, Zhang XF, Pan QZ, Zhao JJ, Jiang SS, Wang Y, Zhang JH, Xia JC(Corresponding). Decreased expression of TRIM3 is associated with poor prognosis in patients with primary hepatocellular carcinoma. Med Oncol. 2014 Aug;31(8):102.

        33.   Mai C, Zhao JJ, Tang XF, Wang W, Pan K, Pan QZ, Zhang XF, Jiang SS, Zhao BW, Li YF, Xia JC(Corresponding), Zhou ZW. Decreased ITIH5 expression is associated with poor prognosisin primary gastric cancer. Med Oncol.2014 Jul;31(7);53.

        34.   Pan K, Wang QJ, Liu Q, Zheng HX, Li YQ, Weng DS, Li JJ, Huang LX, He J, Chen SP, Ke ML, Zeng YX, Xia JC(Corresponding). The phenotype of ex vivo generated cytokine-induced killer cells is associated with overall survival in patients with cancer. Tumour Biol 2014;35(1): 701-7.

        35.   Wang H, Jiang S, Zhang Y, Pan K, Xia JC(Corresponding), Chen M. High expression of thymosin beta 10 predicts poor prognosis for hepatocellular carcinoma after hepatectomy. World J Surg Oncol  2014 Jul 18;12:226.

        36.   Zhao JJ, Pan QZ, Pan K, Weng DS, Wang QJ, Li JJ, Lv L, Wang DD, Zheng HX, Jiang SS, Zhang XF, Xia JC (Corresponding). Interleukin-37 Mediates the Antitumor Activity in Hepatocellular Carcinoma: Role for CD57+ NK Cells. Sci Rep. 2014 Jun 5;4:5177.

        37.   Zheng Y, Wang DD, Wang W, Pan K, Huang CY, Li YF, Wang QJ, Yuan SQ, Jiang SS, Qiu HB, Chen YM, Zhang XF, Zhao BW, Mai C, Xia JC (Corresponding), Zhou ZW. Reduced expression of uroplakin 1A is associated with the poor prognosis of gastric adenocarcinoma patients. PLoS One. 2014 Apr 3;9(4):e93073.

        38.   Pan K, Guan XX, Li YQ, Zhao JJ, Li JJ, Qiu HJ, Weng DS, Wang QJ, Liu Q, Huang LX, He J, Chen SP, Ke ML, Zeng YX, Xia JC (Corresponding). Clinical activity of adjuvant cytokine-induced killer cell (CIK) immunotherapy in patients with post-mastectomy triple-negative breast cancer patients. Clin Cancer Res. 2014 Jun 1;20(11):3003-11.

        39.   Keshari RP, Wang W, Zhang Y, Wang DD, Li YF, Yuan SQ, Qiu HB, Huang CY, Chen YM, Xia JC (Corresponding), Zhou ZW. Decreased Expression of the GATA3 Gene Is Associated with Poor Prognosis in Primary Gastric Adenocarcinoma. PLoS One. 2014 Feb 4;9(2):e87195

        40.   Pan K, Lv L, Zheng HX, Zhao JJ, Pan QZ, Li JJ, Weng DS, Wang DD, Jiang SS, Chang AE, Li Q, Xia JC(Corresponding). OK-432 synergizes with IFN-γ to confer dendritic cells with enhanced antitumor  immunity. Immunol Cell Biol. 2014 Mar;92(3):263-74.

        41.   Wang SH, Lu L, Fan Y, Wicha MS, Cao Z, Chang AE, Xia JC, Baker JR Jr, Li Q.Characterization of a novel transgenic mouse tumor model for targeting HER2+ cancer stem cells. Int J Biol Sci. 2013 Dec 6;10(1):25-32.

        42.   Pan QZ, Pan K, Weng DS, Zhao JJ, Zhang XF, Wang DD, Lv L, Jiang SS, Zheng HX, Xia JC(Corresponding). Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma. Mol Carcinog. 2013 Dec 23.

        43.   Yang XB, Zhao JJ, Huang CY, Wang QJ, Pan K, Wang DD, Pan QZ, Jiang SS, Lv L, Gao X, Chen HW, Yao JQ, Zhi M, Xia JC (Corresponding). Decreased Expression of the FOXO3a Gene Is Associated with Poor Prognosis in Primary Gastric Adenocarcinoma Patients. PLoS One. 2013 Oct 230;8(10): e78158

        44.   Pan QZ, Pan K, Zhao JJ, Chen JG, Li JJ, Lv L, Wang DD, Zheng HX, Jiang SS, Zhang XF, Xia JC (Corresponding). Decreased expression of interleukin-36α correlates with poor prognosis in hepatocellular carcinoma. Cancer Immunol Immunother. 2013 Sep 6.

        45.   Lu L, Pan K, Zheng HX, Li JJ, Qiu HJ, Zhao JJ, Weng DS, Pan QZ, Wang DD, Jiang SS, Chang AE, Li Q, Xia JC (Corresponding). IL-17A promotes immune cell recruitment in human esophageal cancers and the infiltrating dendritic cells represent a positive prognostic marker for patient survival. J Immunother. 2013 Oct;36(8):451-8.

        46.   Huang CY, Zhao JJ, Lv L, Chen YB, Li YF, Jiang SS, Wang W, Pan K, Zheng Y, Zhao BW, Wang DD, Chen YM, Yang L, Zhou ZW, Xia JC (Corresponding). Decreased Expression of AZGP1 Is Associated with Poor Prognosis in Primary Gastric Cancer. PLoS One. 2013 Jul 23;8(7):e69155.

        47.   Pan K, Li YQ, Wang W, Xu L, Zhang YJ, Zheng HX, Zhao JJ, Qiu HJ, Weng DS, Li JJ, Wang QJ, Huang LX, He J, Chen SP, Ke ML, Wu PH, Chen MS, Li SP, Xia JC (Corresponding), Zeng YX. The Efficacy of Cytokine-Induced Killer Cell Infusion as an Adjuvant Therapy for Postoperative Hepatocellular Carcinoma Patients. Ann Surg Oncol. 2013 Jul 27.

        48.   Huang ZM, Li W, Li S, Gao F, Zhou QM, Wu FM, He N, Pan CC, Xia JC, Wu PH, Zhao M. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. J Immunother. 2013 Jun;36(5):287-93.

        49.   Zhang F, Sun XF, Li YQ, Zhen ZJ, Zheng HX, Zhu J, Wang QJ, Lu SY, He J, Wang J, Pan K, Cai RQ, Chen Y, Weng DS, Sun FF, Xia JC (Corresponding). Safety of in vitro amplified HLA-haploidentical donor immune cell infusions for childhood malignancies. Chin J Cancer. 2013 May 27. doi: 10.5732 / cjc.012.10298.

        50.   Zhao JJ, Pan K, Wang QJ, Xu ZD, Weng DS, Li JJ, Li YQ, Xia JC (Corresponding). Effect of anti-asthma Chinese medicine Chuankezhi on the anti-tumor activity of cytokine-induced killer cells. Chin J Cancer. 2013 Mar 8. doi: 10.5732/cjc.012.10249.

        51.   Huang CY, Chen YM, Zhao JJ, Chen YB, Jiang SS, Yan SM, Zhao BW, Pan K, Wang DD, Lv L, Li YF, Wang W, Zhou ZW, Xia JC (Corresponding). Decreased expression of transcription elongation factor a-like 7 is associated with gastric adenocarcinoma prognosis. PLoS One. 2013;8(1):e54671.

        52.   Li JJ, Shan HB, Xu GL, He LJ, Xia JC. Submucosal saline solution injection combined with endosonography for distinguishing between stages T1a and T1b of early esophageal cancer. Gastrointest Endosc. 2013 Jan;77(1):159-60.

        53.   Li JJ, Pan K, Gu MF, Chen MS, Zhao JJ, Wang H, Liang XT, Sun JC, Xia JC (Corresponding). Prognostic value of soluble MICA levels in the serum of patients with advanced hepatocellular carcinoma. Chin J Cancer. 2013 Mar;32(3):141-8.

        54.   Li YF, Wang DD, Zhao BW, Wang W, Huang CY, Chen YM, Zheng Y, Keshari RP, Xia JC (Corresponding), Zhou ZW. High Level of COP1 Expression is Associated with Poor Prognosis in Primary Gastric Cancer. Int J Biol Sci. 2012;8(8):1168-77.

        55.   Li YF, Wang DD, Zhao BW, Wang W, Yuan SQ, Huang CY, Chen YM, Zheng Y, Keshari RP, Xia JC (Corresponding), Zhou ZW. Poor prognosis of gastric adenocarcinoma with decreased expression of AHRR. PLoS One. 2012;7(8):e43555.

        56.   Wang DD, Chen YY, Pan K, Wang W, Chen SP, Chen JG, ZhaoJJ, Lv L, Pan QZ, Li YQ, Wang QJ, Huang LX, Ke ML, He J, Xia JC (Corresponding). Decreased Expression of the ARID1A Gene Is Associated with Poor Prognosis in Primary Gastric Cancer. PLoS One. 2012; 7(7): e40364

        57.   Zhao JJ, Pan K, Wang W, Chen JG, Wu YH, Lv L, Li JJ, Chen YB, Wang DD, Pan QZ, Li XD, Xia JC (Corresponding). The prognostic value of tumor-infiltrating neutrophils in gastric adenocarcinoma after resection. PLoS One. 2012;7(3):e33655.

        58.   Li JJ, Gu MF, Pan K, Liu LZ, Zhang H, Shen WX, Xia JC (Corresponding). Autologous Cytokine-Induced Killer Cell Transfusion in Combination with Gemcitabine plus Cisplatin Regimen Chemotherapy for Metastatic Nasopharyngeal Carcinoma. J Immunotherapy. 2012 Feb-Mar;35(2):189-95.

        59.   Pan K, Liang XT, Zhang HK, Zhao JJ, Wang DD, Li JJ, Lian Q, Chang AE, Li Q, Xia JC (Corresponding).. Characterization of BIN1 as a potential tumor suppressor and prognostic marker in hepatocellular carcinoma. Mol Med. 2012 18:507-18.

        60.   Chen Y, Pan K, Li S, Xia J (Corresponding), Wang W, Chen J, Zhao J, Lü L, Wang D, Pan Q, Wang Q, Li Y, He J, Li Q. Decreased expression of V-set and immunoglobulin domain containing 1 (VSIG1) is associated with poor prognosis in primary gastric cancer. J Surg Oncol. 2012 Sep 1;106(3):286-93.

        61.   Zhao JJ, Pan K, Li JJ, Chen YB, Chen JG, Lv L, Wang DD, Pan QZ, Chen MS, Xia JC (Corresponding). Identification of LZAP as a New Candidate Tumor Suppressor in Hepatocellular Carcinoma. PLoS One. 2011; 6(10): e26608.

        62.   Wang W, Lv L, Pan K, Zhang Y, Zhao JJ, Chen JG, Chen YB, Li YQ, Wang QJ, He J, Chen SP, Xia JC (Corresponding). Reduced expression of transcription factor AP-2α is associated with gastric adenocarcinoma prognosis. PLoS One. 2011; 6(9): e24897.

        63.   Lv L, Pan K, Li XD, She KL, Zhao JJ, Wang W, Chen JG, Chen YB, Yun JP, Xia JC (Corresponding). The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS One. 2011; 6(3): e18219.

        64.   Liang XT, Pan K, Chen MS, Li JJ, Wang H, Zhao JJ, Sun JC, Chen YB, Ma HQ, Wang QJ, Xia JC (Corresponding). Decreased expression of XPO4 is associated with poor prognosis in hepatocellular carcinoma. J Gastroenterol Hepatol. 2011; 26(3): 544-9

        65.   Ma H, Liang X, Chen Y, Pan K, Sun J, Wang H, Wang Q, Li Y, Zhao J, Li J, Chen M, Xia J (Corresponding). Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma. Int J Cancer. 2011; 128(4): 771-7.

        66.   Chen JG, Xia JC (Corresponding), Liang XT, Pan K, Wang W, Lv L, Zhao JJ, Wang QJ, Li YQ, Chen SP, He J, Huang LX, Ke ML, Chen YB, Ma HQ, Zeng ZW, Zhou ZW, Chang AE, Li Q. Intratumoral Expression of IL-17 and Its Prognostic Role in Gastric Adenocarcinoma Patients. Int J Biol Sci. 2011; 7(1): 53-60.

        67.   Ma H, Weng D, Chen Y, Huang W, Pan K, Wang H, Sun J, Wang Q, Zhou Z, Wang H, Xia J (Corresponding). Extensive analysis of D7S486 in primary gastric cancer supports TESTIN as a candidate tumor suppressor gene. Mol Cancer. 2010; 9:190.

        68.   Pan K, Zhao JJ, Wang H, Li JJ, Liang XT, Sun JC, Chen YB, Ma HQ, Liu Q, Xia JC (Corresponding). Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells loaded with hepatocellular carcinoma -derived RNA or cell lysate. Int J Biol Sci. 2010; 6(7): 639-48.

        69.   Sun JC, Liang XT, Pan K, Wang H, Zhao JJ, Li JJ, Ma HQ, Chen YB, Xia JC (Corresponding). High expression level of EDIL3 in HCC predicts poor prognosis of HCC patients. World J Gastroenterol. 2010; 16(36): 4611-5.

        70.   Wang QJ, Wang H, Pan K, Li YQ, Huang LX, Chen SP, He J, Ke ML, Zhao JJ, Li JJ, Sun JC, Liang XT, Ma HQ, Chen YB, Xia JC (Corresponding). Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. Chin J Cancer. 2010; 29(7): 641-8.

        71.   Sun JC, Pan K, Chen MS, Wang QJ, Wang H, Ma HQ, Li YQ, Liang XT, Li JJ, Zhao JJ, Chen YB, Pang XH, Liu WL, Cao Y, Guan XY, Lian QZ, Xia JC (Corresponding). Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells. Cancer Biol Ther. 2010; 10(4): 368-75.

        72.   Ma H, Zhang Y, Wang Q, Li Y, He J, Wang H, Sun J, Pan K, Chen M, Xia J (Corresponding). Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation. Cancer Biol Ther. 2010; 9(11): 903-7.

        73.   Zhang H, Ma H, Wang Q, Chen M, Weng D, Wang H, Zhou J, Li Y, Sun J, Chen Y, Liang X, Zhao J, Pan K, Wang H, Xia J (Corresponding). Analysis of loss of heterozygosity on chromosome 4q in hepatocellular carcinoma using high-throughput SNP array. Oncol Rep. 2010; 23(2): 445-55.

        74.   Zhou J, Weng D, Zhou F, Pan K, Song H, Wang Q, Wang H, Wang H, Li Y, Huang L, Zhang H, Huang W, Xia JC (Corresponding). Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses. Cancer Immunol. Immunother. 2009; 58(10): 1587-97.

        75.   Pan K, Wang H, Liu W, Zhang H, Zhou J, Li J, Weng D, Huang W, Sun J, Liang X, Xia JC (Corresponding). The pivotal role of p38 and NF-κB signal pathways in the maturation of human monocyte-derived dendritic cells stimulated by streptococcal agent OK-432. Immunobiology 2009; 214(5): 350-358.

        76.   Zhang HK, Pan K, Wang H, Weng DS, Song HF, Zhou J, Huang W, Li JJ, Chen MS, Xia JC (Corresponding). Decreased Expression of Ing2 Gene and Its Clinicopathological Significance in Hepatocellular Carcinoma. Cancer Lett. 2008; 261(2): 183-192.

        77.   Weng DS, Zhou J, Zhou QM, Zhao M, Wang QJ, Huang LX, Li YQ, Chen SP, Wu PH, Xia JC (Corresponding). Minimally Invasive Treatment Combined with Cytokine-Induced Killer Cells Therapy Lower the Short-Term Recurrence Rates of Hepatocellular Carcinomas. J Immunother. 2008; 31(1): 63-71.

        78.   Ma HQ, Liang XT, Zhao JJ, Wang H, Sun JC, Chen YB, Pan K, Xia JC (Corresponding). Decreased expression of Neurensin-2 correlates with poor prognosis in hepatocellular carcinoma. World J Gastroenterol. 2009; 15(38): 4844-8.

        79.   Wang H, Pan K, Zhang HK, Weng DS, Zhou J, Li JJ, Huang W, Song HF, Chen MS, Xia JC (Corresponding). Increased Polycomb-Group Oncogene Bmi-1 Expression Correlates with Poor Prognosis in Hepatocellular Carcinoma. J Cancer Res Clin Oncol. 2008; 134(5): 535-541.

        80.   Pan K, Wang H, Chen MS, Zhang HK, Weng DS, Zhou J, Huang W, Li JJ, Song HF, Xia JC (Corresponding). Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008; 134(11):1247-1253

        81.   Weng DS, Li JT, Mai SJ, Pan ZZ, Feng BJ, Feng QS, Huang LX, Wang QJ, Li YQ, Yu XJ, Chen SP, He J, Xia JC (corresponding). Identification of a new target region on the long arm of chromosome 7 in gastric carcinoma by loss of heterozygosity. World J Gastroenterol. 2006; 12(15): 2437-2440.

        82.   Xia JC, Weng DS, Li JT, Qin HD, Mai SJ, Feng BJ, Fan Q, Feng QS, Huang LX, Yu XJ, Pan ZZ, Li YQ, Wang QJ, Zhan YQ, Chen SP, He J, Huang WL, Wu PH, Zeng YX. Loss of heterozygosity analysis of a candidate gastric carcinoma tumor suppressor locus at 7q31. Cancer Genet Cytogenet. 2006; 166(2): 166-172.

        83.   Tanaka Y, Koido S, Xia JC (co-firster author), Ohana M, Liu C, Cote GM, Sawyer DB, Calderwood S, Gong J. Development of Antigen-Specific CD8+ Cytotoxic T Lymphocytes in MHC Class I-Deficient Mice through CD4 to CD8 Conversion. J Immunol. 2004; 172: 7848-7858.

        84.   Xia JC, Tanaka Y, Koido S, Liu C, Mukherjee P, Gendler SJ, Gong J. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol. 2003; 170 (4): 1980-1986. 


        更新日期:2020年2月27日

      訪客通道
      員工通道
      關注腫瘤醫院
      留言建議 ×
      HoMEmenuCopyrights 2015.All rights reserved.More welcome - Collect from power by english Blok number sss85786789633111 Copyright